<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="839">
  <stage>Registered</stage>
  <submitdate>13/09/2005</submitdate>
  <approvaldate>13/09/2005</approvaldate>
  <nctid>NCT00193973</nctid>
  <trial_identification>
    <studytitle>Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma</studytitle>
    <scientifictitle>A Phase 2 Study of Idarubicin Based Combined Modality Therapy in Primary Central Nervous System Lymphoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ALLG LY4</secondaryid>
    <secondaryid>TROG 01.02</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Primary Central Nervous System Lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C
Treatment: other - Radiation Therapy

Active Comparator: 1 - 


Treatment: drugs: Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C
Idarubicin 15mg/m2 days 1, 22. Filgrastim 5mcg/kg until neutrophil recovery days 2, 23. Methotrexate 1g/m2 days 15, 36 and 50.

Treatment: other: Radiation Therapy
Whole brain Irradiation, 30Gy in 20 fractions over 4 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Treatment: other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To estimate the median and 2 year overall survival.</outcome>
      <timepoint>Estimate of survival at 2 years and at 5 years.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Assess acute toxicity.</outcome>
      <timepoint>Interim actute toxicity analyses will be performed at accrual points: 5, 10, 15, 20 and 25 patients.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assess functional indices of living in patients with PCNSL.</outcome>
      <timepoint>Analysis will be at 5 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To estimate the risk of late neurotoxicity relative to results achieved in TROG 92.01.</outcome>
      <timepoint>Analysis at 3 years.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histologically proven primary CNS lymphoma.

          -  Absence of disease outside the CNS.

          -  ECOG performance status 0-3

          -  Negative HIV status.

          -  Peripheral blood counts with granulocytes &gt;1.5 x 109L and platelets &gt; 100 x 109L.
             Serum creatinine &lt;150mmol/L. Serum bilirubin &lt;1.5 times and AST &lt;2 times upper limit
             of normal.

          -  Age &gt;18 and &lt;=70 years.

          -  Patients must give written informed consent.

          -  Corticosteroids prior to histological diagnosis are allowed.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Previous history of malignancy (other than non-melanomatous skin carcinoma, or
             carcinoma in situ of cervix completely excised).

          -  Patients who are pregnant or lactating.

          -  NYHA (New York State Heart Association classification) cardiac failure grade 3

          -  Macroscopic spinal thecal or spinal cord disease.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2001</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>20</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>The Canberra Hospital - Garran</hospital>
    <hospital>Calvary Mater Newcastle - Newcastle</hospital>
    <hospital>Prince of Wales Hospital - Randwick</hospital>
    <hospital>Westmead Hospital - Wentworthville</hospital>
    <hospital>Illawarra Cancer Care Centre - Wollongong</hospital>
    <hospital>Royal Brisbane Hospital - Herston</hospital>
    <hospital>Mater QRI - South Brisbane</hospital>
    <hospital>Premion - Tugun - Tugun</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Andrew Love Cancer Centre, Geelong Hospital - Geelong</hospital>
    <hospital>Peter MacCallum Cancer Centre - Melbourne</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <postcode>2605 - Garran</postcode>
    <postcode>2298 - Newcastle</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>2145 - Wentworthville</postcode>
    <postcode> - Wollongong</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>4224 - Tugun</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3220 - Geelong</postcode>
    <postcode>8006 - Melbourne</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Trans-Tasman Radiation Oncology Group (TROG)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Australasian Leukaemia and Lymphoma Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Idarubicin combined with high dose methotrexate and moderate dose radiotherapy will achieve
      similar survival outcomes but with reduced neurotoxicity compared to regimens using
      methotrexate with high dose radiotherapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00193973</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Peter O'Brien, FRANZCR</name>
      <address>Newcastle Mater Misericordiae Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>